glp 1 agonist delayed gastric emptying My thoughts exclusively --> PPIs aren't working for many patients on GLP-1 therapies! Gastrointestinal effects of GLP-1 receptor

Busetto L, Bettini S, Makaronidis J, Roberts CA, Halford JCG, Batterham RL

The mechanisms of action, results, and considerations for these drugs are detailed in Table 2

Hormone and Metabolic Research , 36(1112), 735741

Its subsequent November 8, 2023 approval as Zepbound for chronic weight management extended these benefits to people with obesity or overweight plus comorbidity

Public Plan Spending Context The Globe and Mail reports that public plans spent $794 million on Ozempic in 2024, and if plans cover Mounjaro, it could cost them an estimated $1.97 billion over three years, about $820 million more than the plans currently spend on comparable drugs over a similar period [Source: theglobeandmail.com/business/economy/article-canada-drug-agency-mounjaro-recommendation-type-2-diabetes/]

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats